Abstract 152P
Background
Neoadjuvant chemoradiotherapy (nCRT) is the standard initial treatment for locally advanced rectal cancer (LARC) to reduce tumor size before surgery. Although some patients achieve complete pathological response and become eligible for organ-preserving strategies, predicting nCRT response remains challenging. The intratumoral genetic heterogeneity (ITGH) has emerged as a potential biomarker in LARC patients. Tumor-infiltrating lymphocytes (TILs) enriched with cytotoxic CD8+ T-cells indicate better prognosis and treatment response. An immunohistochemistry-based score, estimating CD3+ and CD8+ enrichment in LARC TILs, is proposed as a predictive test. Elements from anti-tumoral immune response could serve as potential predictive biomarkers.
Methods
We analyzed 80 primary LARC tumors (18 responders, nCRT-R, versus nonresponders 62, nCRT-NR) through WXS and TCRseq. We evaluated nCRT response, tumor mutation burden (TMB), neoantigen load (NAL), HLA polymorphism, somatic mutation, TCR diversity/clonality, ITGH levels, and DNA mismatch repair deficiency.
Results
We identified six significantly mutated genes (KRAS, APC, TP53, FBXW7, ARID1A, SLITRK6) (p<0.05; FDR<=0.1). Somatic mutations in driver genes, 23 dMMR genes, and COSMIC somatic signatures S6, S15, S20, or S26 did not show any association with nCRT response (p>0.5; Fisher Test). We measured ITGH through MATH score, but no significant difference between nCRT-R and NR (p=0.8; Wilcoxon test) was observed. TMB and NAL were significantly higher in nCRT-NR (p<0.05). HLA somatic mutation did not have a significant impact on antigen presentation and treatment response (8 mutations in 8 patients; Pearson Chi-squared, p=0.76). HLA polymorphism was not relevant (Pearson Chi-squared, p=0.64). Finally, nCRT response was not associated with TCR Shannon diversity or clonality (Wilcoxon test, p=0.25 and p=0.48, respectively); however, we could not quantify CD8+ T-cells.
Conclusions
Gene driver signature, ITGH, or dMMR mutations/signatures were not predictive biomarkers of nCRT response; however, preliminary findings suggest a subset of highly immunogenic nCRT-NR LARCs patients could benefit from immunotherapy.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
R. Perez.
Funding
FAPESP: Fundação de Amparo à Pesquisa do Estado de São Paulo.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
123P - Incidence and outcomes of anaplastic lymphoma kinase (ALK) and ROS 1 positive advanced NSCLC: A real world experience
Presenter: Stalin Chowdary Bala
Session: Cocktail & Poster Display session
Resources:
Abstract
125P - Combination of navitoclax with alpelisib and trametinib to synergistically impair cell viability in high-grade ovarian cancer
Presenter: Lisa Wozelka-Oltjan
Session: Cocktail & Poster Display session
Resources:
Abstract
126P - Effect of sequential antitumoral treatment with immune checkpoint blockade and tyrosine kinase inhibitors in hepatocellular carcinoma
Presenter: Vincenza Ciaramella
Session: Cocktail & Poster Display session
Resources:
Abstract
127P - Novel bone-targeting of activatable sirolimus for targeted therapy of bone-resident cancers
Presenter: Alistare Sadra
Session: Cocktail & Poster Display session
Resources:
Abstract
128P - Network medicine approach identifies small molecule drugs as immune checkpoint inhibitors repurposable for rectal cancer
Presenter: Faheem Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
129P - Repurposing existing therapies for adrenal cancer: Unlocking new possibilities
Presenter: Anupama Samantasinghar
Session: Cocktail & Poster Display session
Resources:
Abstract
130P - Restoration of the mutant p53 protein upon treatment with small molecule modulators
Presenter: Elvina Gilyazova
Session: Cocktail & Poster Display session
Resources:
Abstract
131P - Trop 2 and its overexpression in metastatic colorectal cancer patients (mCRCp): Biological, clinical and therapeutic implications
Presenter: Andrea Mancuso Petricca
Session: Cocktail & Poster Display session
Resources:
Abstract
132P - Novel small molecule modulators for activation of mutant tumor suppressor p53
Presenter: Damir Davletshin
Session: Cocktail & Poster Display session
Resources:
Abstract
133P - Cytotoxic efficacy of artificial vesicles obtained from CAR-T cells by ultrasonication
Presenter: Ekaterina Zmievskaya
Session: Cocktail & Poster Display session
Resources:
Abstract